Supernus, United Therapeutics form partnership to develop UT-15C for hypertension

By Lisa Kerner

Charlotte, N.C., June 13 - Supernus Pharmaceuticals, Inc. said it signed a definitive licensing agreement with United Therapeutics Corp. for the development of UT-15C, United Therapeutics' oral prostacyclin analog, including additional indications.

UT-15C is an oral sustained release formulation of treprostinil, the active ingredient in Remodulin that is marketed for treatment of pulmonary arterial hypertension, according to a company news release.

Under the agreement, Supernus will receive milestone payments and royalties from based on the sales of UT-15C.

Supernus is a specialty pharmaceutical company located in Rockville, Md.

United Therapeutics is a biotechnology company based in Silver Spring, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.